open access

Vol 11, No 2 (2015)
Review paper
Published online: 2015-05-20
Get Citation

Development of anticancer immunotherapy idea

Kamila Wojas-Krawczyk, Paweł Krawczyk
Onkol. Prak. Klin 2015;11(2):69-75.

open access

Vol 11, No 2 (2015)
REVIEW ARTICLES
Published online: 2015-05-20

Abstract

Over the decades, significant evolution of anticancer immunotherapy idea has been seen, involving the gradual discontinuation of active specific immunotherapy methods towards the use of antibodies for immune checkpoints. Clinical studies have shown limited effectiveness of “vaccines” containing antigens or whole tumor cells in the treatment of advanced melanoma, non-small-cell lung cancer and colon cancer as well as many other tumours. Immunotherapy using immune cells encounters major methodological problems, although the development of genetic engineering gives hope for the development of effective methods for adoptive immunotherapy (eg. with modified cytotoxic T lymphocytes). In contrast, the use of anti-CTLA-4, anti-PD-1 and anti-PD-L1 antibodies is possible to obtain long-term disease control in some patients with various types of cancer. The search for predictive factors of different immunotherapy methods is mandatory.

Abstract

Over the decades, significant evolution of anticancer immunotherapy idea has been seen, involving the gradual discontinuation of active specific immunotherapy methods towards the use of antibodies for immune checkpoints. Clinical studies have shown limited effectiveness of “vaccines” containing antigens or whole tumor cells in the treatment of advanced melanoma, non-small-cell lung cancer and colon cancer as well as many other tumours. Immunotherapy using immune cells encounters major methodological problems, although the development of genetic engineering gives hope for the development of effective methods for adoptive immunotherapy (eg. with modified cytotoxic T lymphocytes). In contrast, the use of anti-CTLA-4, anti-PD-1 and anti-PD-L1 antibodies is possible to obtain long-term disease control in some patients with various types of cancer. The search for predictive factors of different immunotherapy methods is mandatory.

Get Citation

Keywords

immunotherapy, cancer, tumour antigens

About this article
Title

Development of anticancer immunotherapy idea

Journal

Oncology in Clinical Practice

Issue

Vol 11, No 2 (2015)

Article type

Review paper

Pages

69-75

Published online

2015-05-20

Bibliographic record

Onkol. Prak. Klin 2015;11(2):69-75.

Keywords

immunotherapy
cancer
tumour antigens

Authors

Kamila Wojas-Krawczyk
Paweł Krawczyk

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl